Tranexamic acid

Tranexamic acid is a prescription medicine that slows the breakdown of blood clots. Clinicians use it to reduce bleeding, not to fix whatever is causing the bleeding. In the United States it appears in three forms that are easy to confuse: tablets you swallow, an injection given by a clinician, and cosmetic serums and creams sold for dark spots. Only the first two are FDA-approved prescription drugs. The serums share the same active ingredient name, but they are regulated as cosmetics, not as medicines.

The short answer for anyone skimming: this is an antifibrinolytic drug, meaning it protects clots that have already formed. Oral tablets are approved for heavy menstrual bleeding that follows a monthly cycle. The injection is approved for short-term use in people with hemophilia around tooth extraction. Other uses, including skin lightening, are off-label.

That split matters because the searches around this drug pull in two very different readers. One is losing too much blood every month and wants to know if a tablet helps. The other has melasma or stubborn dark patches and is comparing a tablet against a cream. The safety picture is not the same for both, and neither is the cost.

What the drug does inside the body

When a blood vessel is damaged, your body lays down a mesh of a protein called fibrin. That mesh is the scaffolding of a clot. Your body also builds in a clean-up system: an enzyme called plasmin dissolves fibrin once the repair is done. In heavy bleeding, that clean-up can run faster than the repair.

Tranexamic acid is a synthetic copy of part of the amino acid lysine. It parks on the lysine binding sites that plasminogen, the inactive form of plasmin, uses to grip fibrin. With those sites blocked, less plasmin gets to work and the clot holds longer. A detailed pharmacology summary is published in the NIH StatPearls monograph on this drug.

Two things follow from that mechanism. First, the drug does not create new clots out of nothing, which is why it is not a blood thinner in reverse. It stabilises what your body already made. Second, in a person who is already prone to clotting, keeping clots intact longer is not always a good thing. That is the source of nearly every serious warning on the label.

The plasmin pathway also touches the skin. Plasmin activity influences the signals that push pigment cells to make more melanin, and it plays a role in the tiny blood vessels that flare after sun exposure. That biology is the reason dermatology researchers began testing it for melasma, as summarised in a peer-reviewed review of dermatologic use.

Approved uses, off-label uses, and how the label frames dosing

The oral tablet carries a US approval for cyclic heavy menstrual bleeding. It is taken only on the heaviest days, not every day of the month. It does not act as a contraceptive, it does not regulate a cycle, and it does not treat fibroids, polyps or a bleeding disorder that may be driving the bleeding. If periods are heavy enough to cause fainting, breathlessness or low iron, the underlying cause still needs a workup; patient guidance from US obstetric specialists explains that evaluation.

The injection is approved for a narrower job: short-term use of two to eight days in people with hemophilia, to reduce or prevent bleeding during and after tooth extraction and to cut the need for replacement clotting factor. It is for intravenous use only, and the label flags medication errors from the wrong route as a specific hazard.

Off-label and protocol-driven use is far broader than the approvals. Hospitals use it in major trauma, surgery, postpartum hemorrhage and some nosebleeds. Skin clinicians prescribe short oral courses for melasma. Some clinicians use it for hereditary angioedema. Off-label prescribing is legal and routine in the United States, but the evidence behind each use varies a lot, and the strength of a hospital trial does not transfer to a cosmetic use.

On dosing, this page will not tell you what to take. The published labeling for the tablet sets a fixed regimen rather than a dose you build up over weeks: 1,300 mg three times a day, for a maximum of five days during a menstrual period, with a reduced amount when kidney function is impaired. The injection is weight-based and given by a clinician. Those are label figures for context only, and the full labeling for every marketed product is posted on the NIH DailyMed labeling database. Your own prescriber sets the regimen, including any adjustment for kidney function.

Tranexamic acid for skin: tablets, compounded creams and cosmetic serums

Search interest here is huge, so it is worth being blun. No product in this family is FDA-approved to treat melasma or dark spots. Oral use for pigment problems is off-label. Compounded creams from a pharmacy are not FDA-approved or reviewed for safety, effectiveness or quality before they are sold, even though the active ingredient itself is an approved drug elsewhere. Over-the-counter serums are cosmetics, and cosmetic claims are not evaluated by regulators the way drug claims are.

What the research suggests, cautiously, is that low-dose oral courses can reduce melasma severity for some patients, and that topical forms are gentler but less consistent, partly because the molecule does not cross the skin barrier easily. A dermatology reference summary of topical and oral use in pigment disorders is published by DermNet. Melasma also relapses, especially without daily sun protection, so no version of this is a one-and-done fix.

If a program offers a compounded blend, the useful questions are which pharmacy makes it, whether that pharmacy is a 503A pharmacy compounding for one patient or a 503B outsourcing facility making batches, and what the other ingredients are. Background on how the two categories are regulated sits in the FDA overview of human drug compounding. You can also compare related dermatology and hormone treatments in our Medication Reference Library.

Side effects: the common complaints and the rare emergencies

Most people who take a short oral course get through it with nothing dramatic. In the trials behind the tablet label, the reports that came up most often were headache, sinus and nasal symptoms, back pain, abdominal pain, muscle and joint pain, muscle cramps, migraine, anemia and fatigue. Nausea, diarrhea and dizziness also appear in patient references such as the Mayo Clinic summary for the oral route. With the injection, low blood pressure can occur if it is given too quickly.

The rare problems are the ones that shape prescribing decisions:

• Blood clots, including deep vein thrombosis in a leg, clots that travel to the lung, heart attack and stroke.
• Clots in the eye, including retinal artery or vein occlusion, which can affect vision.
• Visual or colour vision changes. The label directs that use stop if visual symptoms appear.
• Seizures, reported mainly with intravenous use, higher doses and cardiac surgery, and with accidental injection into the spine.
• Severe allergic reactions, including anaphylaxis, which need emergency care.
• Dizziness strong enough to make driving unsafe.

The honest disadvantage of this drug is not a long side effect list. It is that the medicine treats a symptom rather than a cause, that it works only while you are taking it, and that the group of people who most want relief from heavy bleeding overlaps with the group at higher risk of clots. That is why the screening conversation is not a formality.

Who should avoid it, and what to keep away from it

Labeling for the tablet rules out use in several situations. These are contraindications, not soft cautions:

• Active clotting inside blood vessels, or a history of blood clots such as DVT or pulmonary embolism.
• A built-in tendency to clot, for example a thrombogenic heart valve problem, a thrombogenic heart rhythm problem, or an inherited clotting disorder.
• Current use of a combination hormonal contraceptive, which raises clot risk on its own.
• Acquired defective colour vision, because further vision changes cannot be tracked reliably.
• Known allergy to the drug.
• Bleeding in the space around the brain, where the injection has been linked to brain swelling and infarction.

Interactions are short but serious. Concurrent use with factor IX complex or anti-inhibitor coagulant concentrates raises thrombosis risk, and the labeling says to avoid combining them. Estrogen-containing contraception, hormone therapy and oral tretinoin used in a form of leukemia all push in the same clot-forming direction. A patient-level interaction list is maintained in the Cleveland Clinic reference on the oral tablets.

Practical avoidance, in plain terms: do not drive or operate machinery while you feel dizzy, do not stretch a course past what your prescriber set, do not take someone else’s tablets because their bleeding looked like yours, and tell any surgeon, dentist or urgent care clinician that you are on it. Report any vision change, leg swelling, chest pain or breathlessness straight away rather than waiting for the course to finish. Kidney function matters too, because the drug leaves the body largely through the kidneys.

Pregnancy and breastfeeding need a direct conversation with a clinician. The drug does pass into breast milk, and use in pregnancy is generally reserved for specific clinical situations rather than routine cycle control.

Generic tablets, Lysteda, and the injection

The brand most people run into for the tablet is Lysteda. Generic tranexamic acid tablets are also approved, and a generic approved through the standard pathway has to show the same active ingredient and comparable absorption to the brand. That is the point of the approval process: therapeutically, the generic is expected to behave like the brand at the same strength. The practical differences are usually price, tablet appearance and which manufacturer your pharmacy stocks.

The injection is sold as a generic by several manufacturers and has also been marketed under the brand Cyklokapron. Injections are administered in a clinical setting, not at home, and are not part of any telehealth prescription for periods or pigmentation. Approval details for individual products can be looked up in the FDA Drugs@FDA product database.

Cosmetic serums sit outside all of that. They are not interchangeable with a tablet, they are not dose-equivalent, and switching from one to the other is a clinical decision rather than a product swap.

What tranexamic acid costs without insurance

Cost is the reason many readers land here, so here is how the money actually works. Because advertised figures move, this page pulls tracked self-pay numbers live rather than printing a figure that ages badly.

Lowest tracked self-pay monthly price: . Median across tracked programs: . Programs tracked: .

Four things move a self-pay monthly total more than anything else:

• Brand versus generic. Generic tablets usually cost far less than the branded version of the same molecule.
• How much you actually use. A tablet taken on a few days each cycle consumes a different quantity than a daily off-label skin course, and quantity drives what a pharmacy charges.
• Whether the price is medicine only or a bundle. Some telehealth programs quote a monthly membership that includes the visit, messaging and refills, with medication billed separately by a pharmacy. Others quote one figure that covers both. Comparing a medication-only number against an all-in number is the most common budgeting mistake.
• Add-ons. Lab work, a follow-up consult fee, shipping, and the difference between an introductory rate and the renewal rate all change the second month.

If you want to see what a course costs over a year rather than a month, run the numbers before you commit:

And if you have a plan but are not sure which route is cheaper for you, compare the two paths side by side:

On coverage, be careful with promises. Plans differ by employer, state and formulary tier, and a generic tablet prescribed for heavy bleeding is treated differently from a tablet prescribed off-label for pigmentation, which many plans decline to cover at all. Ask your plan directly about the specific product, the quantity limit and any prior authorisation step before assuming a copay. General background on how US drug benefits are structured is published by the health policy researchers at KFF. Our Free Health Calculators and Sample Savings Report show how the same prescription can land at very different monthly totals depending on route.

How telehealth programs handle this prescription, and what to compare

Prescribing this drug online is legal where a licensed clinician evaluates you in a state where they hold a license. That said, programs differ more than their homepages suggest. The dimensions worth lining up:

• What they treat. Some programs handle heavy menstrual bleeding as part of women’s health. Others only prescribe it as part of a pigmentation plan. A few will not prescribe it at all and will route you to in-person care.
• How they screen clot risk. A thorough intake asks about past clots, family clotting disorders, smoking, migraine with aura, current contraception and hormone therapy. A thin intake that skips contraception questions is a warning sign, given the contraindication.
• Whether labs or referrals are part of the plan. Heavy bleeding often needs iron studies, a blood count and sometimes imaging. A program that never orders anything is treating a symptom blind.
• Who is prescribing. Look for the clinician’s name, license type and state, not just a logo.
• Fulfillment. An approved generic from a retail or mail pharmacy is a different product category from a compounded cream. Ask which pharmacy fills it.
• Follow-up and stopping. How you report a side effect, how vision complaints are handled, and how you cancel a recurring plan.

You can browse the programs that prescribe it, with patient ratings on each page, in the Telehealth Provider Directory. If you want to know how those provider scores are built before you lean on them, the weighting is set out in How Provider Scores Work, and broader comparisons of program models sit in our Independent Editorial Analysis.

Questions to bring to a clinician, and the symptoms that need urgent care

Short visits go better with a list. Useful ones include:

• Given my history, does my clot risk rule this out?
• I use hormonal contraception. Does that change the plan?
• What are we treating, the bleeding itself or a cause we have not found yet?
• How many days of each cycle should I take it, and when do I stop?
• Does my kidney function change what I take?
• What should we check before and during treatment, including iron and vision?
• If this is for melasma, is the plan oral, topical, or both, and for how long?
• What is the total monthly cost, including the visit, and what happens at renewal?

Some symptoms are not for a message queue. Get emergency care for chest pain, sudden breathlessness, coughing blood, swelling or pain in one leg, sudden weakness or trouble speaking, a seizure, sudden vision loss or a change in colour vision, or signs of a severe allergic reaction such as facial swelling and trouble breathing. Also seek prompt care if bleeding continues heavily while on treatment, or if you feel faint, breathless or unusually exhausted, which can point to significant blood loss.

Authoritative sources

• Full US labeling for every marketed product, including approved uses, contraindications and warnings, on DailyMed from the National Library of Medicine.
• Pharmacology, off-label use and adverse effects in the NIH StatPearls clinical monograph.
• Patient-facing dosing and side effect context from Mayo Clinic drug information.

Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.